We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

QuidelOrtho Demonstrates Automated, Sample-To-Result, Multiplex RT-PCR Testing Platform at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 08 Feb 2023
Image: QuidelOrtho is demonstrating how to improve workflow and respond more flexibly and quickly to patient needs (Photo courtesy of QuidelOrtho)
Image: QuidelOrtho is demonstrating how to improve workflow and respond more flexibly and quickly to patient needs (Photo courtesy of QuidelOrtho)

At Medlab Middle East 2023, QuidelOrtho Corporation (San Diego, CA, USA) is showcasing for the first time the benefits of the combined organization’s consolidated portfolio of world-class technologies and platforms, through expanded access to clinical chemistry, immunoassay, molecular diagnostics, immunohematology, donor screening, and point-of-care diagnostics offerings.

At the QuidelOrtho booth, the focus is on the Savanna automated, sample-to-result, multiplex RT-PCR testing platform that performs real-time Polymerization Chain Reaction (PCR) tests by using the Savanna instrument and Savanna assay cartridges. This evolutionary multiplex molecular platform enables professional customers to analyze up to 12 pathogens or targets, plus controls, from a single assay run in less than 30 minutes. After inserting the assay cartridge, the instrument performs sample and reagent preparation, nucleic acid extraction and amplification, real-time detection of RNA or DNA target sequence, and qualitative or quantitative result interpretation from a variety of sample types. The Savanna system is intended to aid in the diagnosis of the related diseases.

QuidelOrtho is also demonstrating the Savanna RVP4 Assay (Respiratory Viral Panel-4), a rapid, multiplexed nucleic acid test intended for use with the Savanna instrument for the simultaneous qualitative detection and differentiation of influenza A (Flu A), influenza B (Flu B), respiratory syncytial virus (RSV), and SARS-CoV-2 RNA isolated from human nasal or nasopharyngeal swabs in media obtained from patients with signs and symptoms of respiratory tract infection. The in vitro diagnostic test is intended to aid in the differential diagnosis of infections with these viruses. The Savanna RVP4 Assay comes in a fully integrated cartridge that is stable at room temperature.

Related Links:
QuidelOrtho Corporation 

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Connectivity Solution
EKF Link
Gold Member
Neonatal Heel Incision Device
Tenderfoot

Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NeoGenomics selected Indica Labs’ HALO AP platform to eable its digital pathology operations through a scalable, cloud-based framework (Photo courtesy of Indica Labs)

Expanded Partnership Scales AI-Powered Digital Pathology for Oncology

Oncology diagnostics rely on pathology and biomarker information to guide personalized treatment. As computational pathology and artificial intelligence (AI) expand insights from tissue analysis, laboratories... Read more